Lineage Reports Q1 Revenue of $1.73M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Reports Q1 revenue $1.73M, consensus $3.6M. "This quarter, we continued to build on our developmental and clinical accomplishments. Most notably, we applied our proprietary cell manufacturing technology platform, AlloSCOPE(TM) (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), to launch COR1, our new, wholly-owned corneal endothelial cell therapy program. COR1 is a preclinical asset which we believe benefits from our existing ophthalmology and manufacturing expertise and represents a natural next application of our platform. We also achieved our first milestone with our AlloSCOPE 5D manufacturing initiative, aimed at addressing the challenges of large scale production of undifferentiated pluripotent stem cells. If successful at a larger scale, the overall goal is to leverage this initiative, together with a differentiation protocol, to address the insufficient supply of islet cells needed to support a potential treatment of Type 1 Diabetes," stated Brian M. Culley, Lineage CEO.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LCTX
Wall Street analysts forecast LCTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.330
Low
3.00
Averages
4.50
High
9.00
Current: 1.330
Low
3.00
Averages
4.50
High
9.00
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cell Therapies Propel Growth in Anti-Aging Market
- Market Growth Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio, in collaboration with Austrianova, has completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at developing cell therapies for age-related diseases.
- Focus on Neurodegenerative Diseases: Analysts project the neurodegenerative disease treatment market will grow from $58.4 billion in 2025 to $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
See More
Lineage Cell Therapeutics Expands Manufacturing Platform and Launches CORE1 Program
- Manufacturing Expansion: Lineage Cell Therapeutics Inc (LCTX) successfully expanded its Alloscope manufacturing platform, leading to the launch of the CORE1 corneal endothelial cell transplant program, marking a significant advancement in the cell therapy sector and potentially enhancing its market competitiveness.
- Internal Milestone Achieved: The company met its first internal milestone with the ILT1 manufacturing initiative, showcasing progress in its manufacturing capabilities, which will support subsequent product development and bolster investor confidence.
- Strong Cash Position: LCTX holds a robust cash position of $53.4 million, expected to sustain operations into Q2 2028, with potential additional funding from existing warrants and milestone payments, ensuring continued investment in research and development.
- Challenges and Uncertainties: While the OPERGEN program shows promising disease-modifying effects in patients with dry AMD, its future remains uncertain, particularly regarding the advancement into multicenter controlled trials, facing challenges in recruitment and scaling production.
See More
Lineage Cell Therapeutics Q1 2026 Earnings Call Insights
- Platform Expansion and New Initiatives: Lineage successfully expanded its AlloSCOPE cell manufacturing platform, leading to the launch of the new COR1 corneal endothelial cell transplant program, marking a strategic move into the ophthalmology sector that is expected to enhance market competitiveness.
- Partner Dynamics: Significant progress with Roche and Genentech, as the latter described OpRegen as a potentially disease-modifying treatment for the first time in their recent presentation, indicating increased confidence from partners that may accelerate clinical advancements.
- Financial Position and Spending: As of March 31, 2026, Lineage's cash reserves stood at $53.4 million, expected to support operations into Q2 2028, with potential warrant proceeds of approximately $32 million enhancing financial flexibility.
- R&D Spending and Revenue: Q1 total revenues were approximately $1.7 million, primarily driven by a new research collaboration agreement with Demant, while R&D expenses totaled $4.2 million, reflecting ongoing investments in new projects despite a net loss of $4.8 million, highlighting the need to monitor profitability.
See More
Lineage Cell Therapeutics Q1 Earnings Report Analysis
- Disappointing Earnings: Lineage Cell Therapeutics reported a Q1 GAAP EPS of -$0.03, missing expectations by $0.01, indicating ongoing challenges in profitability that may undermine investor confidence.
- Weak Revenue Growth: The company generated $1.72 million in revenue for Q1, a 14.7% year-over-year increase, yet it fell short of expectations by $1.36 million, reflecting insufficient market demand that could limit future cash inflows.
- Rising Operating Expenses: Total operating expenses for Q1 2026 reached $9.3 million, up $1.3 million from $8.0 million in Q1 2025, primarily driven by increases in R&D and G&A expenses, which may impact the company's financial flexibility.
- Increased R&D Spending: R&D expenses amounted to $4.2 million, an increase of $1.1 million year-over-year, mainly for the OPC1 and ReSonance programs, highlighting a commitment to innovation, though the actual impact on future product development remains to be seen.
See More
Lineage Cell Therapeutics to Announce Q1 Earnings on May 12
- Earnings Announcement Schedule: Lineage Cell Therapeutics (LCTX) is set to announce its Q1 2023 earnings on May 12 after market close, with consensus EPS estimate at -$0.02 and revenue estimate at $3.08 million, reflecting the company's commitment to financial transparency.
- Performance Beat Record: Over the past year, LCTX has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, indicating the company's stability in managing market expectations and performance, which may enhance investor confidence.
- Cash Runway Extension: Lineage has successfully extended its cash runway into Q2 2028, providing financial security as it advances OpRegen and new pipeline programs, demonstrating its ongoing investment in R&D and strategic planning.
- Industry Engagement: LCTX's participation in the FFB Retinal Therapeutics Innovation Summit enhances its visibility and influence in the biotechnology sector, potentially attracting more investor interest in its future growth prospects.
See More
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova's joint venture Klothonova will present the latest data on their α-Klotho anti-aging therapy at the September 2026 Klotho Conference, marking the company's ongoing innovation and leadership in the anti-aging sector.
- Significant Market Potential: The global longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, representing a compound annual growth rate of 12.84%, highlighting the vast opportunities for cellular therapies and gene editing technologies.
- Technological Platform Advantage: Klothonova employs the Cell-in-a-Box® technology to protect genetically modified cells, ensuring they continuously produce α-Klotho protein in the body, thus providing a sustainable solution for anti-aging treatments and enhancing market competitiveness.
- Diverse Product Line: In addition to the α-Klotho program, Avaí Bio's Insulinova project targets diabetes, directly overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine, further solidifying the company's market position.
See More
Cell Therapies Propel Growth in Anti-Aging Market
- Market Growth Potential: The global cell therapy market was valued at approximately $4.7 billion in 2023 and is expected to exceed $20 billion by 2030, indicating strong interest from biotech firms and investors in cellular repair and regeneration therapies.
- Anti-Aging Therapy Progress: Avaí Bio, in collaboration with Austrianova, has completed the Master Cell Bank (MCB) of α-Klotho protein-overexpressing cells, marking a significant milestone that will advance clinical trial processes aimed at developing cell therapies for age-related diseases.
- Focus on Neurodegenerative Diseases: Analysts project the neurodegenerative disease treatment market will grow from $58.4 billion in 2025 to $85 billion by 2032, reflecting a surge in investment towards disease-modifying therapies, particularly in Alzheimer's and Parkinson's disease.
- Clinical Trial Developments: BioAge Labs' BGE-102 demonstrated significant reductions in inflammatory biomarkers in its Phase 1 trial, with plans to initiate a Phase 2 cardiovascular risk trial in the first half of 2026 to further validate its therapeutic potential.
See More
Lineage Cell Therapeutics Expands Manufacturing Platform and Launches CORE1 Program
- Manufacturing Expansion: Lineage Cell Therapeutics Inc (LCTX) successfully expanded its Alloscope manufacturing platform, leading to the launch of the CORE1 corneal endothelial cell transplant program, marking a significant advancement in the cell therapy sector and potentially enhancing its market competitiveness.
- Internal Milestone Achieved: The company met its first internal milestone with the ILT1 manufacturing initiative, showcasing progress in its manufacturing capabilities, which will support subsequent product development and bolster investor confidence.
- Strong Cash Position: LCTX holds a robust cash position of $53.4 million, expected to sustain operations into Q2 2028, with potential additional funding from existing warrants and milestone payments, ensuring continued investment in research and development.
- Challenges and Uncertainties: While the OPERGEN program shows promising disease-modifying effects in patients with dry AMD, its future remains uncertain, particularly regarding the advancement into multicenter controlled trials, facing challenges in recruitment and scaling production.
See More
Lineage Cell Therapeutics Q1 2026 Earnings Call Insights
- Platform Expansion and New Initiatives: Lineage successfully expanded its AlloSCOPE cell manufacturing platform, leading to the launch of the new COR1 corneal endothelial cell transplant program, marking a strategic move into the ophthalmology sector that is expected to enhance market competitiveness.
- Partner Dynamics: Significant progress with Roche and Genentech, as the latter described OpRegen as a potentially disease-modifying treatment for the first time in their recent presentation, indicating increased confidence from partners that may accelerate clinical advancements.
- Financial Position and Spending: As of March 31, 2026, Lineage's cash reserves stood at $53.4 million, expected to support operations into Q2 2028, with potential warrant proceeds of approximately $32 million enhancing financial flexibility.
- R&D Spending and Revenue: Q1 total revenues were approximately $1.7 million, primarily driven by a new research collaboration agreement with Demant, while R&D expenses totaled $4.2 million, reflecting ongoing investments in new projects despite a net loss of $4.8 million, highlighting the need to monitor profitability.
See More
Lineage Cell Therapeutics Q1 Earnings Report Analysis
- Disappointing Earnings: Lineage Cell Therapeutics reported a Q1 GAAP EPS of -$0.03, missing expectations by $0.01, indicating ongoing challenges in profitability that may undermine investor confidence.
- Weak Revenue Growth: The company generated $1.72 million in revenue for Q1, a 14.7% year-over-year increase, yet it fell short of expectations by $1.36 million, reflecting insufficient market demand that could limit future cash inflows.
- Rising Operating Expenses: Total operating expenses for Q1 2026 reached $9.3 million, up $1.3 million from $8.0 million in Q1 2025, primarily driven by increases in R&D and G&A expenses, which may impact the company's financial flexibility.
- Increased R&D Spending: R&D expenses amounted to $4.2 million, an increase of $1.1 million year-over-year, mainly for the OPC1 and ReSonance programs, highlighting a commitment to innovation, though the actual impact on future product development remains to be seen.
See More
Lineage Cell Therapeutics to Announce Q1 Earnings on May 12
- Earnings Announcement Schedule: Lineage Cell Therapeutics (LCTX) is set to announce its Q1 2023 earnings on May 12 after market close, with consensus EPS estimate at -$0.02 and revenue estimate at $3.08 million, reflecting the company's commitment to financial transparency.
- Performance Beat Record: Over the past year, LCTX has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, indicating the company's stability in managing market expectations and performance, which may enhance investor confidence.
- Cash Runway Extension: Lineage has successfully extended its cash runway into Q2 2028, providing financial security as it advances OpRegen and new pipeline programs, demonstrating its ongoing investment in R&D and strategic planning.
- Industry Engagement: LCTX's participation in the FFB Retinal Therapeutics Innovation Summit enhances its visibility and influence in the biotechnology sector, potentially attracting more investor interest in its future growth prospects.
See More
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova's joint venture Klothonova will present the latest data on their α-Klotho anti-aging therapy at the September 2026 Klotho Conference, marking the company's ongoing innovation and leadership in the anti-aging sector.
- Significant Market Potential: The global longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, representing a compound annual growth rate of 12.84%, highlighting the vast opportunities for cellular therapies and gene editing technologies.
- Technological Platform Advantage: Klothonova employs the Cell-in-a-Box® technology to protect genetically modified cells, ensuring they continuously produce α-Klotho protein in the body, thus providing a sustainable solution for anti-aging treatments and enhancing market competitiveness.
- Diverse Product Line: In addition to the α-Klotho program, Avaí Bio's Insulinova project targets diabetes, directly overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine, further solidifying the company's market position.
See More
